Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells

doi:10.5246/jcps.2017.11.093

Journal of Chinese Pharmaceutical Sciences ›› 2017, Vol. 26 ›› Issue (11): 827-833.DOI: 10.5246/jcps.2017.11.093

• Original articles • Previous Articles Next Articles

Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells

Daiying Zhou¹, Li Ding¹, Xi Wang^1*, Juan Ma¹, Wolin Huang¹, Susan Goodin², Xi Zheng^3*

1. Guangdong Food and Drug Vocational College, Guangzhou 510520, China
2. Rutgers Cancer Institute of New Jersey, USA
3. Susan Lehman Cullman Laboratory for Cancer Research, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, USA

Received:2017-07-18 Revised:2017-10-16 Online:2017-11-30 Published:2017-10-27
Contact: Tel.: +732-445-3400(233); +86-020-28854939, Fax: +732-445-0687; +86-020-37216565, E-mail: xizheng@pharmacy.rutgers.edu; wangx@gdyzy.edu.cn
Supported by:
The National Cancer Institute of China (Grant No. P30-CA072720), the National Natural Science Foundation of China (Grant No. 81272452), and the PhD Start-up Fund of Natural Science Foundation of Guangdong Province, China (Grant No. 2014A030310329).

Abstract

Abstract:

Cancer of the prostate gland is a leading cause of death. In the present study, we studied the effects and mechanisms of curcumin analogue E10, docetaxel or their combination on prostate cancer (PC)-3 cells. Treatment of PC-3 cells with E10 or docetaxel resulted in growth inhibition in a concentration-reliant fashion. Combinations of E10 and docetaxel inhibited the growth of PC-3 cells in a synergistic manner. Effects of a combination of E10 and docetaxel were associated with synergistic inhibition of the transcriptional activity of nuclear factor-kappa B (NF-κB), and robust reductions in the levels of B-cell lymphoma-2 (Bcl-2) were found in PC-3 cells treated with a combination of E10 and docetaxel. Our data indicated that the effects of E10 in combination with docetaxel on PC-3 cells were associated with inhibition of NF-κB and Bcl-2. Further studies using suitable animal models are necessary to determine the in vivo effect of this combination.

Key words: Combination treatment, Prostate cancer, Curcumin analogue, Docetaxel, Synergistic effect

CLC Number:

R962

Supporting:

Daiying Zhou, Li Ding, Xi Wang, Juan Ma, Wolin Huang, Susan Goodin, Xi Zheng. Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(11): 827-833.

References

[1] Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. CA Cancer J. Clin. 2014, 64, 9-29.

[2] Stein, M.N.; Goodin, S.; DiPaola, R.S. Clin. Cancer Res. 2012, 18, 1848-1854.

[3] Thomas, B.M.; Smith, C.; Evans, J.; Button, M.R.; Kumar, S.; Palaniappan, N.; Staffurth, J.; Tanguay, J.S.; Lester, J.F. Med. Oncol. 2013, 30, 1-6.

[4] Kuttan, R.; Bhanumathy, P.; Nirmala, K.; George, M.C. Cancer Lett. 1985, 29, 197-202.

[5] Huang, M.T.; Smart, R.C.; Wong, C.Q.; Conney, A.H. Cancer Res. 1988, 48, 5941-5946.

[6] Leite, K.R.; Chade, D.C.; Sanudo, A.; Sakiyama, B.Y.; Batocchio, G.; Srougi, M. Int. Braz. J. Urol. 2009, 35, 599-607.

[7] Zhou, D.Y.; Zhao, S.Q.; Du, Z.Y.; Zheng, X.; Zhang, K. Oncology Lett. 2016, 11, 4160-4166.

[8] Agrawal, D.K.; Mishra, P.K. Med. Res. Rev. 2010, 30, 818-860.

[9] Anand, P.; Sundaram, C.; Jhurani, S.; Kunnumakkara, A.B.; Aggarwal, B.B. Cancer Lett. 2008, 267, 133-164.

[10] Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Clin. Cancer Res. 2008, 14, 4491-4499.

[11] Wei, X.C.; Du, Z.Y.; Zheng, X.; Cui, X.X.; Conney, A.H.; Zhang, K. Eur. J. Med. Chem. 2012, 53, 235-245.

[12] Ikezoe, T.; Hisatake, Y.; Takeuchi, T.; Ohtsuki, Y.; Yang, Y.; Said, J.W.; Taguchi, H.; Koeffler, H.P. Cancer Res. 2004, 64, 7426-7431.

[13] Tannock, I.F.; de Wit, R.; Berry, W.R.; Horti, J.; Pluzanska, A.; Chi, K.N.; Oudard, S.; Théodore, C.; James, N.D.; Turesson, I. N. Engl. J. Med. 2004, 351, 1502-1512.

[14] Kim, S.M.; Lee, S.Y.; Cho, J.S.; Son, S.M.; Choi, S.S.; Yun, Y.P.; Yoo, H.S.; Oh, K.W.; Han, S.B.; Hong, J.T. Eur. J. Pharmacol. 2010, 631, 1-9.

[15] Ganansia-Leymarie, V.; Bischoff, P.; Bergerat, J.P.; Holl, V. Curr. Med. Chem. Anti Cancer Agents. 2003, 3, 291-306.

[16] Montero, A.; Fossella, F.; Hortobagyi, G.; Valero, V. Lancet Oncol. 2005, 6, 229-239.

[17] Tedesco, K.; Thor, A.; Johnson, D.; Shyr, Y.; Blum, K.; Goldstein, L.; Gradishar, W.; Nicholson, B.; Merkel, D.; Murrey, D. J. Clin. Oncol. 2004, 22, 1071-1077.

[18] Ryan, D.P.; Kulke, M.H.; Fuchs, C.S.; Grossbard, M.L.; Grossman, S.R.; Morgan, J.A.; Earle, C.C.; Shivdasani, R.; Kim, H.; Mayer, R.J. Cancer. 2002, 94, 97-103.

[19] Hasima, N.; Aggarwal, B.B. Int. J. Biochem. Mol. Biol. 2012, 3, 328.

[20] Wei, X.; Zhou, D.; Wang, H.; Ding, N.; Cui, X.X.; Wang, H.; Verano, M.; Zhang, K.; Conney, A.H.; Zheng, X.; Du, Z.Y. Anticancer Res. 2013, 33, 1343-1350.

[21] Zheng, X.; Cui, X.X.; Avila, G.E.; Huang, M.T.; Liu, Y.; Patel, J.; Kong, A.N.; Paulino, R.; Shih, W.J.; Lin, Y.; Rabson, A.B.; Reddy, B.S.; Conney, A.H. Clin. Cancer Res. 2007, 13, 5480-5487.

[22] Zhao, L.; Wientjes, M.G.; Au, J.L. Clin. Cancer Res. 2004, 10, 7994-8004.

[23] McDonnell, T.J.; Troncoso, P.; Brisbay, S.M.; Logothetis, C.; Chung, L.W.; Hsieh, J.T.; Tu, S.M.; Campbell, M.L. Cancer Res. 1992, 52, 6940-6944.

[24] Chen, X.; Liu, Y.; Wu, J.; Huang, H.R.; Du, Z.Y.; Zhang, K.; Zhou, D.Y.; Hang, K.; Goonin, S.; Zheng, X. Cancer Genomics. Proteomics. 2016, 13, 151-160.

[25] Connors, S.K.; Chornokur, G.; Kumar, N.B. Nutr. Cancer. 2012, 64, 4-22.

[26] DiDonato, J.A.; Mercurio, F.; Karin, M. Immunol. Rev. 2012, 246, 379-400.

[27] Ross, J.S.; Kallakury, B.V.; Sheehan, C.E.; Fisher, H.A.; Kaufman, R.P.; Kaur, P.; Gray, K.; Stringer, B. Clin. Cancer Res. 2004, 10, 2466-2472.

[28] Shukla, S.; MacLennan, G.T.; Fu, P.; Patel, J.; Marengo, S.R.; Resnick, M.I.; Gupta, S. Neoplasia. 2004, 6, 390-400.

[29] Fradet, V.; Lessard, L.; Bégin, L.R.; Karakiewicz, P.; Masson, A.M.; Saad, F. Clin Cancer Res. 2004, 10, 8460-8464.

[30] Catz, S.D.; Johnson, J.L. Oncogene. 2001, 20, 7342-7351.

Synergistic effects of a curcumin analogue and docetaxel on growth inhibition of human prostate cancer cells

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Ciyan Peng, Jing Chen, Sini Li, Jianhe Li, Liubao Peng. Evidence-based pharmacoeconomic evaluation of palbociclib in combination with letrozole versus docetaxel in combination with epirubicin in the first-line treatment of advanced breast cancer with epirubicin [J]. Journal of Chinese Pharmaceutical Sciences, 2023, 32(3): 214-222.
[2]	Yajie Liu, Yu Wang, Jiajia Li, Xiaoqing Xu, Xinru Li. Preparation and evaluation of doxorubicin-luminespib co-loaded multivesicular liposomes [J]. Journal of Chinese Pharmaceutical Sciences, 2021, 30(9): 736-742.
[3]	Shen Lin, Xin Rao, Yiyuan Li, Xiuhua Weng, Changlian Wang. Cost-effectiveness analysis of second-line chemotherapy strategies for patients with advanced non-squamous non-small cell lung cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2020, 29(8): 542-553.
[4]	Haitao Hou, Zibing Song, Jieqin Ding, Dengguo Wei, Sheng Hu, Qianqian Zhai, Xiali Yue. Berberine enhances the activity of Sunitinib by targeting telomere G-quadruplex [J]. Journal of Chinese Pharmaceutical Sciences, 2019, 28(5): 289-297.
[5]	Jiongxi Lei, Shuangchen Cong, Maoyuan Song, Wenxi Zhang, Guanghua Peng, Yuanyuan Zhang, Mengya Yin, Jiaxing Wang, Jiajia Li, Xinru Li. Preparation, characterization and evaluation of liposomal doxorubicin and harmine that show synergistic activity in vitro [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(9): 666-674.
[6]	Qiao Zou, Yifan Chen, Xiaoqing Zheng, Binyuan Xu, Yuxi Liu, Huihui Zeng. Butaselen and cisplatin synergistically inhibit human cancer cells proliferation [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(8): 595-604.
[7]	Xin Li, Ning Pang, Ji Li, Xianrong Qi. Characterization of amphiphilic dendrimer modified PEG-PLA nanoparticles prepared by a double emulsion-solvent evaporation method [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(7): 521-527.
[8]	Yihua Hong, Tongtong Liu, Yanjun Liu, Jingxuan Wu, Xiaogai Yang. Vanadium compounds induce stronger growth suppression in PTEN-deficient prostate cancer cells by ROS-mediated mechanism [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(6): 432-439.
[9]	Weina Yu, Youyi Xiong, Zhuo Chen, Fang Wang. Alpha-1-acid glycoprotein as potential predictive biomarker of docetaxel adverse effects in breast cancer patients [J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(12): 895-899.
[10]	Asia Abed Al-Mahmood, Limin Shu, Hyuck Kim, Christina Ramirez, Douglas Pung, Yue Guo, Wenji Li, Ah-Ng Tony Kong. Prostate cancer and chemoprevention by natural dietary phytochemicals [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(9): 633-650.
[11]	Fang Wang, Zhuo Chen, Lin Li, Mingzhi Zhu, Youyi Xiong, Yuanting Gu. Pharmacokinetically determined docetaxel exposure as a predictor of hematologic toxicity in Chinese patients with early stage breast cancer [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(7): 512-516.
[12]	Ying Huang, Zhengyuan Su, Tienyuan Wu, Constance Lay-Lay Saw, Ah-Ng Tony Kong. Mechanisms of prostate carcinogenesis and its prevention by a γ-tocopherol-rich mixture of tocopherols in TRAMP mice [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(3): 170-177.
[13]	Yuanxin Li, Zifei Han, Chao Tian, Zhili Zhang, Junyi Liu. Design, synthesis and evaluation of novel non-ATP competitive CHK1 inhibitors as chemotherapy sensitizing agents [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(10): 726-736.
[14]	Sujit Nair, Ah-Ng Tony Kong. Pharmacometrics of nutraceutical sulforaphane and its implications in prostate cancer prevention [J]. Journal of Chinese Pharmaceutical Sciences, 2016, 25(1): 12-22.
[15]	Sujit Nair, Celine Liew, Tin-Oo Khor, Li Cai, Ah-Ng Tony Kong. Elucidation of regulatory interaction networks underlying human prostate adenocarcinoma [J]. Journal of Chinese Pharmaceutical Sciences, 2015, 24(1): 12-27.